Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
  • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
  • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D207/24—Oxygen or sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
  • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
  • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Definitions

• the invention relates to compounds of the formula
• Alkylene chain means in which 1 to 3 C atoms can be replaced by N and / or 1 to 2 C atoms by 1 to 2 O and / or 1 to 2 S atoms, but at most up to 3 C atoms be replaced and in addition one, two or three times
• M is a phenyl ring or an aromatic heterocycle which can contain 1-2 N, O and / or S atoms,
• R 1 H, shark, A OR 2 , N (R 2 ) 2 , N0 2 , CN, COOR 2 , CON (R 2 ) 2 ,
• a unbranched or branched alkyl having 1 -10 C atoms, in which one or two CH 2 groups by O or S atoms and / or by -CH CH groups and / or 1-7 H atoms by F can be replaced
• 0 denotes 1, 2 or 3, and their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios.
• the invention was based on the task of finding new compounds with valuable properties, in particular those which can be used for the production of medicaments. It has been found that the compounds of the formula I and their salts have very valuable pharmacological properties with good tolerability. In particular, they show factor Xa inhibitory properties and can therefore be used to combat and prevent thromboembolic
• Inflammation apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication can be used.
• Inhibitors of the coagulation factors factor VIIa, factor IXa and thrombin of the blood coagulation cascade are Inhibitors of the coagulation factors factor VIIa, factor IXa and thrombin of the blood coagulation cascade.
• Aromatic amidine derivatives with antithrombotic activity are e.g. from EP 0 540 051 B1, WO 98/28269, WO 00/71508, WO 00/71511, WO 00/71493, WO 00/71507, WO 00/71509, WO 00/71512, WO 00/71515 or WO 00 / 71516 known.
• Cyclic guanidines for the treatment of thromboembolic diseases are e.g. described in WO 97/08165.
• Aromatic heterocycles with factor Xa inhibitory activity are e.g. known from WO 96/10022. Substituted N - [(aminoiminomethyl) phenylalkylj-azaheterocyclylamides as factor Xa inhibitors are described in WO 96/40679.
• the antithrombotic and anticoagulant effect of the compounds according to the invention is attributed to the inhibitory effect against the activated coagulation protease, known under the name factor Xa, or to the inhibition of other activated serine proteases such as factor VIII, factor IXa or thrombin.
• Factor Xa is one of the proteases involved in the complex process of blood clotting. Factor Xa catalyzes the conversion of prothrombin to thrombin. Thrombin cleaves fibrinogen into fibrin monomers which, after cross-linking, make an elementary contribution to thrombus formation. A Activation of thrombin can lead to the occurrence of thromboembolic disorders. However, inhibition of thrombin can inhibit fibrin formation involved in thrombus formation.
• the measurement of the inhibition of thrombin can e.g. using the method of G.F. Cousins et al. in Circulation 1996, 94, 1705-1712.
• Inhibition of factor Xa can thus prevent thrombin from being formed.
• the compounds of formula I according to the invention and their salts interfere with the blood coagulation process by inhibiting factor Xa and thus inhibit the formation of thrombi.
• the inhibition of factor Xa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods.
• a suitable method is e.g. by J. Hauptmann et al. in Thrombosis and Haemostasis 1990, 63, 220-223.
• the measurement of the inhibition of factor Xa can e.g. using the method of T. Hara et al. in thromb. Haemostas. 1994, 71, 314-319.
• the coagulation factor Vlla initiates the extrinsic part of the coagulation cascade after binding to the tissue factor and contributes to the activation of the
• Factor X to factor Xa.
• An inhibition of factor VIIa thus prevents the development of factor Xa and thus a subsequent one
• Coagulation factor IXa is generated in the intrinsic coagulation cascade and is also involved in the activation of factor X to factor Xa. Inhibition of factor IXa can therefore otherwise prevent factor Xa from being formed.
• the inhibition of factor IXa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be carried out according to customary in vitro or in vivo
• the compounds according to the invention can furthermore be used for the treatment of tumors, tumor diseases and / or tumor metastases.
• the compounds of formula I can be used as active pharmaceutical ingredients in human and veterinary medicine, in particular for Treatment and prevention of thromboembolic disorders such as
• Thrombosis myocardial ischemia, unstable angina and thrombosis-based stroke.
• the compounds of the invention are also used for treatment or
• Prophylaxis of atherosclerotic diseases such as coronary arterial disease, cerebral arterial disease or peripheral arterial disease are used.
• the compounds are also used in combination with other thrombolytics for myocardial infarction, furthermore for prophylaxis for reocclusion after thrombolysis, percutaneous transluminal angioplasty (PTCA) and coronary bypass surgery.
• PTCA percutaneous transluminal angioplasty
• the compounds according to the invention are also used for the prevention of rethrombosis in microsurgery, also as anticoagulants in connection with artificial organs or in hemodialysis.
• the compounds are also used in the cleaning of catheters and medical devices in patients in vivo, or as anticoagulants for the preservation of blood, plasma and other blood products in vitro.
• the compounds according to the invention are also used in diseases in which blood coagulation makes a decisive contribution to the course of the disease or is a source of secondary pathology, such as e.g. cancer including metastasis, inflammatory diseases including arthritis and diabetes.
• the compounds according to the invention are also used to treat migraines (F. Morales-Asin et al., Headache, 40, 2000, 45- In the treatment of the diseases described, the compounds according to the invention are also used in combination with other thrombolytically active compounds, such as, for example, the “tissue plasminogen activator” t-PA, modified t-PA, streptokinase or urokinase.
• t-PA tissue plasminogen activator
• modified t-PA modified t-PA
• streptokinase or urokinase urokinase
• Simultaneous administration with aspirin is particularly preferred in order to prevent recurrence of thrombus formation.
• the compounds according to the invention are also used in combination with blood platelet glycoprotein receptor (IIb / IIla) antagonists which inhibit blood platelet aggregation.
• IIb / IIla blood platelet glycoprotein receptor
• the invention relates to the compounds of the formula I and their salts and to a process for the preparation of compounds of the formula I • according to claims 1-20 and their pharmaceutically usable derivatives, solvates and stereoisomers, characterized in that a) for the preparation of a compound of the formula I, in which W denotes -OC (R 2 ) - or -NR 2 C (R 2 ) 2 -,
• Z is OH or NHR 2 and R 1 , R 2 , D and M have the meanings given in Claim 1, with the proviso that if a further OH and / or amino group is present, this is protected, with a compound of the formula
• L is Cl, Br or I and R 2 , X, Y and T have the meanings given in Claim 1,
• Means OH group and R 1 , D, M and W have the meanings given in Claim 1, with the proviso that if a further OH and / or amino group is present, this is protected,
• Z'-YT V wherein Z 'denotes NHR 2 or NHR 2 C (R 3 ) 2 and R 2 , Y and T have the meanings given in claim 1, and then optionally splits off a protective group,
• the invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds.
• Solvates of the compounds are understood to mean the addition of inert solvent molecules to the compounds, which are formed on account of their mutual attraction. Solvates are e.g. Mono- or dihydrates or alcoholates.
• compositions are e.g. the salts of the compounds according to the invention and also so-called prodrug compounds.
• Prodrug derivatives are understood with z. B. alkyl or acyl groups, sugars or oligopeptides modified compounds of formula I, which in the organism quickly to the effective invention
• the invention also relates to mixtures of the invention
• radicals that occur more than once such as A
• the meanings are independent of one another.
• radicals or parameters D, M, W, X, Y, T, R 1 have the meanings given in the formula I, unless expressly stated otherwise.
• the ring M is preferably phenyl.
• Single substitution with A or NH 2 is very particularly preferred.
• A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1 - or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1, 1, 2- or 1, 2,2-trimethylpropyl, more preferably for example Trifluoromethyl.
• Cycloalkyl preferably means cyclopropyl, cyclobutyl, cyclopentyl,
• Alkylene preferably means methylene, ethylene, propylene, butylene, pentylene or hexylene, furthermore branched alkylene.
• COR 2 means, for example, CHO or -COA.
• -COA acyl
• acyl preferably means acetyl, propionyl, but also butyryl
• Pentanoyl hexanoyl or e.g. Benzoyl.
• A is preferably alkyl having 1, 2, 3 or 4 carbon atoms.
• R 1 is preferably H or - [C (R 3 ) 2 ] n -N (R 3 ) 2 , particularly preferably H or CH 2 NH 2 .
• W preferably denotes -C (R 2 ) 2 -, - [C (R 2a ) 2 ] 2 -, -OC (R 2a ) 2 - or -NR 2a C (R 2a ) 2 -, in which
• R 2a is H, A 'or Ar', A 'alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms and being 1-7 H atoms
• F can be replaced and Ar 'unsubstituted or mono- or disubstituted by shark
• W particularly preferably denotes -OCHR 2a - or -NHCHR 2a -, in which
• a 'alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms and where 1-7 H atoms can be replaced by F and
• X preferably denotes CONH, CONHCH, CH 2 NH or CH 2 NHCH 2 , very particularly preferably CONH.
• Y is preferably alkylene or ar-diyl, particularly preferably
• Methylene ethylene, propylene or unsubstituted or simply substituted by A, Cl or F, 1,4-phenylene, and also pyridine-diyl, preferably pyridine-2,5-diyI.
• Y in particular means 1, 3- or 1, 4-phenylene which is unsubstituted or simply substituted by methyl, ethyl, propyl, Cl or F.
• Ar means e.g. unsubstituted phenyl, naphthyl or biphenyl, further preferably e.g. by A, fluorine, chlorine, bromine, iodine, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, nitro, cyan,
• Het means e.g. 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1 -, 2, 4- or 5-imidazolyl, 1 -, 3-, 4- or 5-pyrazolyl, 2nd -, 4- or 5-
• the heterocyclic radicals can also be partially or completely hydrogenated.
• Het can, for. B. also mean 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2 - or -3-furyl, 1, 3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2 - or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1, 4
• T further particularly preferably means, for example, 2-imino-piperidin-1-yl, 2-imino-pyrrolidin-1-yl, 2-imino-1 H-pyridin-1-yl, 3-imino-morpholin-4-yl, 4 - Imino-1 H-pyridin-1-yl, 2,6-diimino-piperidin1-yl, 2-imino-piperazin-1-yl, 2,6-diimino-piperazin-1-yl, 2,5-diimino- pyrrolidin-1-yl, 2-imino-1, 3-oxazolidin-3-yl, 3-imino-2H-pyridazin-2-yl, 2-imino-azepan-1-yl, 2-hydroxy-6-imino piperazin-1-yl or 2-methoxy-6-imino-piperazin-1 -yl, 2-imino-piperidin-1-yi is very particularly preferred, as are the corresponding hydroxyimin
• the compounds of formula I can have one or more chiral centers and therefore exist in various stereoisomeric forms.
• Formula I encompasses all of these forms.
• the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
• Id D denotes a saturated, fully or partially unsaturated 3 to 4-membered alkylene chain in which 1 to 3 carbon atoms are represented by N and / or 1 to 2 carbon atoms by 1 to 2 O and / or 1 to 2 S atoms can be replaced, but at most up to 3 C atoms can be replaced and a one, two or three-fold substitution of the alkylene chain and / or a nitrogen therein by A or NH 2 may additionally occur;
• -NH-N CH-
• -0-N CH- or -CH 2 -CH 2 - means, and where, if D is present, a simple substitution by NH 2 may additionally occur at D;
• R 1 is H or - [C (R 3 )] n -N (R 3 ) 2 ;
• Ar ' is phenyl or benzyl which is unsubstituted or mono- or disubstituted by shark;
• Y is phenylene which is unsubstituted or mono- or disubstituted by A, Cl or F;
• R 2b is H, -CH 2 CH 2 NA ' 2 , OH or OA', A 'alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, where 1 -7 H atoms can be replaced by F. ;
• -NH-N CH-
• -0-N CH- or and where, if D is present, a simple substitution by NH 2 can additionally occur at D;
• M is a phenyl ring, R 1 H or CH 2 NH 2 , W -OC (R 2a ) 2 - or -NR 2 C (R 2a ) 2 -,
• the invention furthermore relates in particular to those compounds of the formula I in which at least one of the abovementioned
• Radicals has one of the preferred meanings given above.
• a 'alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms having 1, 2, 3, 4, 5 or 6 carbon atoms
• A is unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms can be replaced by F, n is O or l;
• a 'alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms having 1, 2, 3, 4, 5 or 6 carbon atoms
• A is unbranched or branched alkyl having 1 -6 C atoms, in which 1-7 H atoms can be replaced by F, n is 0 or 1;
• R 1 CN, NH 2 , CH 2 NH 2 , CH 2 CH 2 NH 2 , unsubstituted or monosubstituted by OH
• a 'alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms having 1, 2, 3, 4, 5 or 6 carbon atoms
• A is unbranched or branched alkyl having 1 -6 C atoms, in which 1 -7 H atoms can be replaced by F, n is O or 1;
• X is CH 2 or CH (phenyl)
• a ' is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms
• A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms; missing in lae D,
• X is CH 2 or CH (phenyl)
• a 'alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms having 1, 2, 3, 4, 5 or 6 carbon atoms
• A is alkyl with 1, 2, 3, 4, 5 or 6 carbon atoms
• R 1 CN, NH 2 , CH 2 NH 2 , CH 2 CH 2 NH 2 , unsubstituted or monosubstituted by OH
• R 2 H A or - (CH 2 ) n -Ar, W -OC (R 2 ) 2 - or -NR 2 C (R 2 ) 2 -,
• A is unbranched or branched alkyl having 1 -6 C atoms, in which 1-7 H atoms can be replaced by F, n is 0 or 1;
• the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
• the starting compounds of the formulas II, III, IV and V are generally known. If they are new, they can be manufactured according to methods known per se.
• the invention therefore also relates to compounds of the formula VI and their salts.
• a base of the formula VI can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
• So inorganic acids can be used, for example sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, especially aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g.
• the reaction is usually carried out in an inert solvent
• an acid binding agent preferably an alkali or
• a weak acid of the alkali or alkaline earth metals preferably potassium, sodium, calcium or cesium.
• an organic base such as triethylamine, dimethylaniline, pyridine or quinoline or an excess of the phenol component of the formula II or the alkylation derivative of the formula III can also be favorable.
• the reaction time is between a few minutes and 14 days, the reaction temperature is between about 0 ° and 150 °, normally between 20 ° and 130 °.
• Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol),
• Ethylene glycol dimethyl ether diglyme
• Ketones such as acetone or butanone
• Amides such as acetamide, dimethylacetamide or dimethylformamide (DMF); Nitriles such as acetonitrile
• Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulfide
• Carboxylic acids such as formic acid or acetic acid
• Nitro compounds such as nitromethane or nitrobenzene
• Esters such as ethyl acetate or mixtures of the solvents mentioned.
• Compounds of the formula I can furthermore preferably be obtained by reacting compounds of the formula IV with compounds of the formula V.
• the reaction is usually carried out in an inert solvent and under conditions as stated above.
• L is preferably Cl, Br, I or a free or a reactively modified OH group such as e.g. an activated ester, an imidazolide or alkylsulfonyloxy with 1-6 C atoms
• Activated esters are conveniently formed in situ, e.g. B. by adding HOBt or N-hydroxysuccinimide.
• the reaction is usually carried out in an inert solvent, in the presence of an acid-binding agent, preferably an organic base such as DIPEA, triethylamine, dimethylaniline, pyridine or quinoline or an excess of the carboxy component of the formula IV.
• an acid-binding agent preferably an organic base such as DIPEA, triethylamine, dimethylaniline, pyridine or quinoline or an excess of the carboxy component of the formula IV.
• an alkali metal or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline earth metals preferably of potassium, sodium, calcium or cesium, can be favorable.
• the reaction time is between a few minutes and 14 days
• the reaction temperature is between about -30 ° and 140 °, normally between -10 ° and 90 °, in particular between about 0 ° and about 70 °.
• the above-mentioned are suitable as inert solvents.
• Preferred starting materials for solvolysis or hydrogenolysis are those which otherwise correspond to the formula I, but instead of one or more free amino and / or hydroxyl groups contain corresponding protected amino and / or hydroxyl groups, preferably those which instead of an H atom, which is connected to an N atom carry an amino protective group, in particular those which carry an R'-N group instead of an HN group, in which R 'represents an amino protective group, and / or those which have one instead of the H atom Hydroxy group carry a hydroxy protecting group, e.g. those which correspond to the formula I, but instead of a group -COOH carry a group -COOR "in which R" denotes a hydroxyl protective group.
• Preferred starting materials are also the oxadiazole derivatives, which can be converted into the corresponding amidino compounds.
• amino protecting group is generally known and refers to groups which are suitable for protecting (blocking) an amino group from chemical reactions, but which are easily removable after the desired chemical reaction at other locations on the
• acyl group is related to to understand the present procedure in the broadest sense. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and especially alkoxycarbonyl, aryloxycarbonyl and above all
• Alkanoyl such as acetyl, propionyl, butyryl; Aralkanoyl such as phenylacetyl; Aroyl such as benzoyl or toluyl; Aryloxyalkanoyl such as POA; Alkoxycarbonyl like
• Methoxycarbonyl ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butyloxycarbonyl), 2-iodoethoxycarbonyl; Aralkyloxycarbonyl such as CBZ
• Carbobenzoxy 4-methoxybenzyloxycarbonyl, FMOC; Arylsulfonyl like
• Preferred amino protecting groups are BOC and Mtr, furthermore CBZ,
• hydroxyl protecting group is also generally known and refers to groups which are suitable for protecting a hydroxyl group from chemical reactions, but which are easily removable after the desired chemical reaction at other points in the
• hydroxy protecting groups include Benzyl, 4-methoxybenzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, with benzyl and tert-butyl being particularly preferred.
• Tetrahydrofuran or dioxane Tetrahydrofuran or dioxane, amides such as DMF, halogenated hydrocarbons such as dichloromethane, and also alcohols such as methanol, ethanol or isopropanol, and water. Mixtures of the abovementioned solvents are also suitable. TFA is preferably used in excess without the addition of another solvent, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid in a ratio of 9: 1.
• the reaction temperatures for the cleavage are advantageously between about 0 and about 50 °, preferably between 15 and 30 ° (room temperature).
• the groups BOC, OBut and Mtr can e.g. B. preferably with TFA in dichloromethane or with about 3 to 5N HCl in dioxane at 15-30 °, the FMOC group with an about 5 to 50% solution of
• Hydrogenolytically removable protective groups can, for. B. by treatment with hydrogen in the presence of a catalyst (z. B. a noble metal catalyst such as palladium, advantageously on a support such as coal).
• a catalyst z. B. a noble metal catalyst such as palladium, advantageously on a support such as coal.
• Suitable solvents are the above, especially z. B. alcohols such as methanol or ethanol or amides such as DMF. Hydrogenolysis is usually done with
• Suitable inert solvents are, for example, hydrocarbons such as hexane,
• Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or
• Glycol ethers such as ethylene glycol monomethyl or monoethyl ether
• Esters can e.g. are saponified with acetic acid or with NaOH or KOH in water, water-THF or water-dioxane at temperatures between 0 and 100 °.
• a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
• acids that provide physiologically acceptable salts are suitable for this implementation.
• So inorganic acids can be used, for example Sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, for example
• Formic acid acetic acid, propionic acid, pivalic acid, diethyl acetic acid,
• Lactic acid tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalene mono- and disulfonic acid, laurylsulfonic acid.
• Salts with physiologically unacceptable acids e.g. Picrates can be used for the isolation and / or purification of the compounds of the formula I.
• compounds of formula I with bases can be converted into the corresponding metal, in particular alkali metal or alkaline earth metal, or into the corresponding ammonium salts.
• physiologically harmless organic bases e.g. Ethanolamine can be used.
• the pharmaceutical activity of the racemates or the stereoisomers of the compounds according to the invention can differ, it may be desirable to use the enantiomers.
• the end product or even the intermediates can be converted into enantiomeric compounds by chemical agents known to the person skilled in the art or physical measures, separated or already used as such in the synthesis.
• diastereomers are formed from the mixture by reaction with an optically active release agent.
• Suitable release agents are e.g. optically active acids, such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (e.g. N-benzoylproline or N-benzenesulfonylproline) or the various optically active camphorsulfonic acids.
• Chromatographic separation of enantiomers with the aid of an optically active separating agent e.g.
• Aqueous or alcoholic solvent mixtures such as e.g. Hexane / 1 sopropanol / acetonitrile e.g. in the ratio 82: 15: 3.
• the invention furthermore relates to the use of the compounds of the formula I and / or their physiologically acceptable salts for the production of a medicament (pharmaceutical preparation), in particular in a non-chemical way. They can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active ingredients.
• the invention further relates to medicaments containing at least one compound of the formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, and, if appropriate, carriers and / or auxiliaries.
• Organic or inorganic substances in question which are suitable for enteral (for example oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin,
• Carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
• Tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops are used for oral use, suppositories for rectal use, solutions for parenteral use, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for which topical application ointments, creams or powder or as a nasal spray.
• the new compounds can also be lyophilized and the resulting lyophilisates e.g. can be used for the production of injectables.
• the specified preparations can be sterilized and / or auxiliary substances such as lubricants, preservatives. Contain stabilizing and / or wetting agents, emulsifiers, salts to influence the osmotic pressure, buffer substances, coloring, flavoring and / or several other active ingredients, e.g. one or more vitamins.
• the compounds of the formula I and their physiologically acceptable salts can be used to combat and prevent thrombo-embolic diseases such as thrombosis, myocardial infarction,
• Arteriosclerosis inflammation, apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication, tumors, tumor diseases and / or tumor metastases can be used.
• the substances according to the invention are generally preferably administered in doses between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit.
• the daily dosage is preferably between about 0.02 and 10 mg / kg body weight.
• the specific dose for each patient depends on a variety of factors, such as the effectiveness of the special connection used, age, body weight, general health, gender, diet, time and route of administration, rate of excretion,
• the invention furthermore relates to medicaments comprising at least one compound of the formula I and / or their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, and at least one further active pharmaceutical ingredient.
• the invention also relates to a set (kit) consisting of separate packs of
• the set contains suitable containers, such as boxes or boxes, individual bottles, bags or ampoules.
• the set can e.g. contain separate ampoules, in each of which an effective amount of a compound of formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all proportions, and an effective amount of another active pharmaceutical ingredient is dissolved or in lyophilized form.
• the invention furthermore relates to the use of compounds of the formula I and / or their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, for the manufacture of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication, migraines, tumors, tumor diseases and / or tumor metastases, in combination with at least one further active pharmaceutical ingredient.
• Example A Injection glasses
• a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection glass contains 5 mg of active ingredient.
• a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
• a solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH 2 P0 • 2 H 2 0, 28.48 g of Na 2 HP0 4 • 12 H 2 0 and 0.1 g of benzalkonium chloride in 940 ml double distilled water. It is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
• Example D ointment
• Example E tablets
• a mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
• Example F coated tablets
• Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
• Example G capsules
• each capsule contains 20 mg of the active ingredient.
• a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pain & Pain Management (AREA)
• Urology & Nephrology (AREA)
• Biomedical Technology (AREA)
• Oncology (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pyrrole Compounds (AREA)
• Hydrogenated Pyridines (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=28051091

Family Applications (1)

Country Status (10)

Cited By (5)

Families Citing this family (5)

Citations (5)

• 2002
  • 2002-04-04 DE DE10214832A patent/DE10214832A1/de not_active Withdrawn
• 2003
  • 2003-03-07 ES ES03709758T patent/ES2271539T3/es not_active Expired - Lifetime
  • 2003-03-07 CA CA002481026A patent/CA2481026A1/en not_active Abandoned
  • 2003-03-07 AU AU2003214102A patent/AU2003214102A1/en not_active Abandoned
  • 2003-03-07 JP JP2003581773A patent/JP2005528377A/ja active Pending
  • 2003-03-07 DE DE50304858T patent/DE50304858D1/de not_active Expired - Fee Related
  • 2003-03-07 US US10/510,046 patent/US20050176760A1/en not_active Abandoned
  • 2003-03-07 AT AT03709758T patent/ATE337779T1/de not_active IP Right Cessation
  • 2003-03-07 WO PCT/EP2003/002349 patent/WO2003084533A1/de not_active Ceased
  • 2003-03-07 EP EP03709758A patent/EP1490056B1/de not_active Expired - Lifetime
  • 2003-04-04 AR ARP030101174A patent/AR039249A1/es unknown

Patent Citations (5)

Also Published As

Similar Documents

Legal Events